Radiopharm Theranostics Statistics
Total Valuation
RADX has a market cap or net worth of $15.08 million. The enterprise value is $10.56 million.
| Market Cap | 15.08M |
| Enterprise Value | 10.56M |
Important Dates
The next estimated earnings date is Thursday, November 26, 2026.
| Earnings Date | Nov 26, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
RADX has 4.34 billion shares outstanding. The number of shares has increased by 47.68% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 4.34B |
| Shares Change (YoY) | +47.68% |
| Shares Change (QoQ) | +39.34% |
| Owned by Insiders (%) | 4.85% |
| Owned by Institutions (%) | 8.65% |
| Float | 3.59B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.69 |
| Forward PS | 1.67 |
| PB Ratio | 0.98 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.19 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.16
| Current Ratio | 1.16 |
| Quick Ratio | 1.14 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -471.16 |
Financial Efficiency
Return on equity (ROE) is -174.71% and return on invested capital (ROIC) is -101.54%.
| Return on Equity (ROE) | -174.71% |
| Return on Assets (ROA) | -45.15% |
| Return on Invested Capital (ROIC) | -101.54% |
| Return on Capital Employed (ROCE) | -128.42% |
| Weighted Average Cost of Capital (WACC) | 8.37% |
| Revenue Per Employee | $635,723 |
| Profits Per Employee | -$2.81M |
| Employee Count | 14 |
| Asset Turnover | 0.18 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, RADX has paid $37,662 in taxes.
| Income Tax | 37,662 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -84.23% in the last 52 weeks. The beta is 0.75, so RADX's price volatility has been lower than the market average.
| Beta (5Y) | 0.75 |
| 52-Week Price Change | -84.23% |
| 50-Day Moving Average | 2.14 |
| 200-Day Moving Average | 4.02 |
| Relative Strength Index (RSI) | 22.54 |
| Average Volume (20 Days) | 62,239 |
Short Selling Information
The latest short interest is 42,220, so 0.33% of the outstanding shares have been sold short.
| Short Interest | 42,220 |
| Short Previous Month | 30,426 |
| Short % of Shares Out | 0.33% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.64 |
Income Statement
In the last 12 months, RADX had revenue of $8.90 million and -$39.40 million in losses. Loss per share was -$0.01.
| Revenue | 8.90M |
| Gross Profit | -23.75M |
| Operating Income | -36.64M |
| Pretax Income | -39.36M |
| Net Income | -39.40M |
| EBITDA | -34.76M |
| EBIT | -36.64M |
| Loss Per Share | -$0.01 |
Balance Sheet
The company has $2.86 million in cash and no debt, with a net cash position of $2.86 million or $0.00 per share.
| Cash & Cash Equivalents | 2.86M |
| Total Debt | n/a |
| Net Cash | 2.86M |
| Net Cash Per Share | $0.00 |
| Equity (Book Value) | 15.44M |
| Book Value Per Share | 0.00 |
| Working Capital | 2.10M |
Cash Flow
| Operating Cash Flow | -36.81M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 1.89M |
| Net Borrowing | n/a |
| Free Cash Flow | -36.81M |
| FCF Per Share | -$0.01 |
Margins
| Gross Margin | -266.89% |
| Operating Margin | -411.63% |
| Pretax Margin | -442.25% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
RADX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -47.68% |
| Shareholder Yield | -47.68% |
| Earnings Yield | -261.21% |
| FCF Yield | -244.08% |
Analyst Forecast
The average price target for RADX is $17.04, which is 1,435.14% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $17.04 |
| Price Target Difference | 1,435.14% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | 246.53% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
RADX has an Altman Z-Score of -6.16 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -6.16 |
| Piotroski F-Score | 2 |